Day One Biopharmaceuticals, Inc. DAWN
Apr 24, 2026, 9:30 AM EDT
52-week range unavailable
- YTD
- +131.01%
- 1 year
- +172.53%
- Market cap
- 2.22B
- Profit margin
- -55.98%
- YTD return
- +131.01%
- 1-year return
- +172.53%
- Open
- 21.53
- Previous close
- 21.53
- Day's range
- 21.53 – 21.53
1Y +12.54 (+139.49%)
Key statistics
- Enterprise value
- 2.03B
- PEG ratio
- 0.60
- Price / sales
- 0.00
- Price / book
- 5.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -15.82%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy0
- Buy0
- Hold8
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 5, 2026 | Mar 31, 2026 | -0.31 | -0.35 | -0.04 | -12.90% |
| Feb 24, 2026 | Dec 31, 2025 | -0.17 | -0.20 | -0.03 | -17.65% |
| Nov 4, 2025 | Sep 30, 2025 | -0.27839 | -0.19 | +0.09 | +31.75% |
| Aug 5, 2025 | Jun 30, 2025 | -0.35 | -0.29 | +0.06 | +17.14% |
| May 6, 2025 | Mar 31, 2025 | -0.46 | -0.35 | +0.11 | +23.91% |
| Feb 25, 2025 | Dec 31, 2024 | -0.35 | -0.69 | -0.34 | -97.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 11, 2026 | JP Morgan | down | Overweight | Neutral |
| Mar 10, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 9, 2026 | Wedbush | down | Outperform | Neutral |
| Mar 6, 2026 | Jones Trading | down | Buy | Hold |
| Mar 6, 2026 | Needham | down | Buy | Hold |
| Feb 25, 2026 | Wedbush | main | Outperform | Outperform |
About Day One Biopharmaceuticals, Inc.
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 181
- Website
- dayonebio.com
News
Servier completes the acquisition of Day One Biopharmaceuticals 
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders? 
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High – What’s Next? 
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN 
This VICI Properties Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday 
Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More 
Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen 
Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More 
Are DAWN and TALK Obtaining Fair Deals for their Shareholders? 
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
Your note
Sign in to keep a note on DAWN — it syncs with the Stock Master app.